ABL Diagnostics Announces Renewal of U.S. Patent (US 8,859,198 B2) for Hepatitis B Genotyping and Antiviral Resistance
Reinforcing long-term IP strength in molecular diagnostics and supporting global laboratory partners WOIPPY, FRANCE, June 15, 2026 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a specialist in molecular diagnostics, bioinformatics and …